EUVIMEDEUVIMED entdecken
Crossref

A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis

Bowen Ding, Xiaomeng Liu, Zhe Li, Xinru Xie, Jiaqi Li, Jiaqian Wang, Shouyi Li, Pengyu Wang, Yongjie Xie, Xiaoqing Ma, Hongwei Wang, Chengzhi Xie und 5 weitere

Drug Resistance Updates · 2025-07 · 81 · 101252

DOI: 10.1016/j.drup.2025.101252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-07. Verfasst von Bowen Ding und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Drug…. Hauptthemen laut MEDLINE: Prodrugs, Membrane Proteins, Organoplatinum Compounds. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, TianJin Education Committee, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum(II) (Pt(II)) drugs, such as cisplatin and oxaliplatin, played critical roles in cancer therapy; however, their efficacy is often limited by significant toxicity and the development of drug resistance. Recently, multi-target platinum(IV) (Pt(IV)) complexes, particularly those optimized with axial ligands, have emerged as promising alternatives enhancing tumor selectivity and drug stability. In this study, we synthesized a series of novel platinum(IV) prodrugs, gramine-platinum(IV), by incorporating gramine-a natural indole alkaloid that antagonizes TGF-β receptors I and II to inhibit the TGF-β signaling pathway-as an axial ligand. Among them, compound 8 (referred to as GP) was screened out to have the best antitumor activity. GP not only enhances the therapeutic efficacy of platinum(II) drugs but also targets TGF-β signaling. Our findings demonstrate that GP rapidly enters cells and preferentially accumulates in critical subcellular compartments, such as the nucleus and mitochondria, significantly amplifying its therapeutic impact. Notably, GP exhibits great tumor accumulation compared to cisplatin and oxaliplatin, with minimal uptake in normal tissues, highlighting its superior tumor specificity with reduced systemic toxicity. This unique characteristic enables GP to enhance therapeutic efficiency through multiple modalities, including strengthening DNA damage, reducing mitochondrial membrane potential, promoting apoptosis, and arresting cell cycle in the S phase. Moreover, GP activates the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling (cGAS-STING) pathway, enhancing antigen presentation and fostering robust anti-tumor immune responses. In mouse models of pancreatic and breast cancer, GP significantly inhibits tumor growth and triggers strong innate immune activation. By combining GP with anti-PD-1 therapy, immunotherapy-resistant tumors are rendered responsive, leading to a pronounced suppression of tumor growth. Overall, GP not only amplifies the DNA-damaging effects of platinum(II) drugs but also elicits durable immune responses, establishing itself as a promising chemo-immune-combined strategy for treating pancreatic and breast cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsMembrane ProteinsOrganoplatinum CompoundsAnimalsHumansMiceTransforming Growth Factor betaSignal TransductionNucleotidyltransferasesCell Line, TumorFemaleImmunotherapyXenograft Model Antitumor AssaysAntineoplastic AgentsOxaliplatinCisplatinCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseSTING Protein

Stichwörter der Autor:innen

GramineImmune regulationPt(IV) prodrugTGF-β targeting

Substanzen

ProdrugsTransforming Growth Factor betaMembrane ProteinsOrganoplatinum CompoundsNucleotidyltransferasesAntineoplastic AgentsOxaliplatinCisplatincGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase

Autor:innen und Institutionen

  • Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key…
  • Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China; Key Laborat…
  • Department of Chemical Biology and Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049, China. Electronic address: 721wangym@aliyun.com.

Förderung

  • Key Technologies Research and Development Program
  • TianJin Education Committee
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Ding, B., Liu, X., Li, Z., Xie, X., Li, J., Wang, J., Li, S., Wang, P., Xie, Y., Ma, X., Wang, H., Xie, C., Qiao, X., Wang, Y., Xu, J., Feng, Y., & Hao, J. (2025). A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis. Drug Resistance Updates, 81, 101252. https://doi.org/10.1016/j.drup.2025.101252

Vancouver

Ding B, Liu X, Li Z, Xie X, Li J, Wang J, et al. A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis. Drug Resistance Updates. 2025;81:101252. doi:10.1016/j.drup.2025.101252

BibTeX
@article{Ding2025,
  author = {Ding, Bowen and Liu, Xiaomeng and Li, Zhe and Xie, Xinru and Li, Jiaqi and Wang, Jiaqian and Li, Shouyi and Wang, Pengyu and Xie, Yongjie and Ma, Xiaoqing and Wang, Hongwei and Xie, Chengzhi and Qiao, Xin and Wang, Yumin and Xu, Jingyuan and Feng, Yukuan and Hao, Jihui},
  title = {A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {81},
  pages = {101252},
  doi = {10.1016/j.drup.2025.101252}
}
Kostenlos starten →